ZTS Zoetis Inc.
ZTS Zoetis Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
Market read
Scan convergence 2 scans as of 2026-10-23 1 bear 1 neutral converging
POC $77.02 · VWAP $97.35 · -16.8% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
1 related campaign
ZTS Price Structure
Loading timeframes…
Peers
Every watchlist ZTS belongs to, members best 30-day change first — ZTS highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@livestock-disease
@healthcare
Reported the quarter ending 2026-06-30: revenue $2.47B, diluted EPS $1.65, net income $691M (SEC filing). Across the print the stock moved -2.3% (close before → first close after).
full note →Against street estimates
How ZTS's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
Recent news
Headlines about ZTS from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 14 days ago · Oct 9
- Zoetis - Zoetis Announces Second Quarter 2026 Results
- Zoetis Inc. (ZTS) Q2 FY2026 earnings call transcript
- Zoetis Inc (ZTS) (Q2 2026) Earnings Call Highlights: Navigating Market Headwinds with Strategic ...
- Zoetis Inc. (ZTS) stock price, news, quote and history - Yahoo Finance
- Zoetis Announces First Quarter 2026 Results
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
ZTS research tape
43 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.